Levine Media Group

@SpelaMirosevic founder of the CTNNB1 Foundation, shares how a parent-led effort built an international research team, raised millions, and brought a gene therapy for CTNNB1 syndrome to a first-in-human trial. @GlobalGenes #RARECast globalgenes.org/raredaily/a-mo…

Alzheimer’s R&D has focused on memory loss—but for many families, the breaking point is psychosis: hallucinations and delusions that make home care impossible. @AcadiaPharma R&D head Liz Thompson discusses new approaches to treating Alzheimer’s psychosis. thebioreport.podbean.com/e/targeting-ps…

Here's what you may have missed in March from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/editing-…

Theresa Strong @FPWRUK discusses the org's efforts to develop an ASO therapy for Schaaf-Yang syndrome and how patient-led organizations can drive translational programs for ultra-rare conditions. @GlobalGenes #RARECast globalgenes.org/raredaily/how-…

Attorney Harrison James of @WisnerBaum discusses a national civil RICO class action against Takeda and Eli Lilly, what it took to apply a statute intended for mobsters to drugmakers, and the implications the case may have for the pharmaceutical industry. thebioreport.podbean.com/e/a-class-acti…

Hematologist oncologist Marina Kremyanskaya and PV patient advocate Nona Baker discuss the chronic rare blood cancer, how it reshapes everyday life for patients, and the promise of new therapies in development. @GlobalGenes #RARECast globalgenes.org/raredaily/from…

@BenZeskind @Immuneering discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated.

@hopeforpdcd CEO Frances Pimentel and parent board member Kim Higbee share how PDCD families are reacting to the FDA’s refusal of an experimental therapy—and why endpoints in a study miss the lived patient benefits. @globalgenes #RARECast globalgenes.org/raredaily/6523…

@GoogleCloud @ShwetaManiar on why life sci cos must treat AI as a strategic upgrade to de-risk science rather than a tool for improving efficiency—and how messy data, culture change, and multi-agent systems speed the path from discovery to patients. youtube.com/watch?v=zZrZaC…

Richard Freed @RheumaGen_ , discusses role of HLA genes in autoimmune diseases, how the company’s gene-editing therapies work, and its lead program in rheumatoid arthritis. thebioreport.podbean.com/e/editing-away…

Rachel McMinn @NeurogeneInc , about Rett syndrome, the company’s technology for controlling gene expression, and the encouraging data they’ve seen so far. @GlobalGenes #RARECast globalgenes.org/raredaily/reop…

Here's what you may have missed in February from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/hitting-…

@tigerminer , lead author of @wef0orum paper, discusses how smarter collection, sharing and analysis of rare disease data could unlock multi-trillion dollar gains in human health—and what it’ll take to rally global stakeholders. @GlobalGenes #RARECast globalgenes.org/raredaily/a-da…

.@scotchmcclure @MaxwellBiosci , explains why AI is becoming the engine of modern drug development—speeding discovery, filtering noise in massive datasets, and taking on more of the scientific process under clear vision and guardrails. youtube.com/watch?v=A9lE-0…

Leukemia survivor and @Columbia hematologist-oncologist @TheDoctorIsVin is reimagining blood cancer care—moving from blunt chemo to precision strategies that rewire malignant cells, epigenetic programs, and their ecosystems. thebioreport.podbean.com/e/reprogrammin…

Rajani Aatre of Michigan Medicine discusses the importance of cascade genetic testing, ethical tensions around its use, and the question of how to share life changing genetic information with relatives. @GlobalGenes #RARECast globalgenes.org/raredaily/when…

.@TernsPharma 's CEO Amy Burroughs discusses a strategic shift from metabolic disease to focus on the company's experimental therapy for chronic myeloid leukemia and how she is charting a clear path toward a broader oncology future. thebioreport.podbean.com/e/a-strategic-…

.@CartesianTX Carsten Brunn discusses how the company’s RNA‑engineered CAR T cells target the root cause of autoimmune diseases, data from its study in myasthenia gravis, and the potential to expand indications. @GlobalGenes #RARECast globalgenes.org/raredaily/chan…

Drew McCormick, head of data and analytics for @EVERSANAcompany , sits down with Nagaraja Srivatsan to trace the company’s AI journey from classic predictive modeling in its data and analytics business to an enterprise-wide strategy. youtube.com/watch?v=eKuWnd…

Ron Cooper, CEO of enGene, discusses the company’s experimental gene therapy for non–muscle invasive bladder cancer, and how its dual payload is meant to activate both an innate and adaptive immune response in the bladder. thebioreport.podbean.com/e/a-one-two-ge…